An open-label extension trial to assess the long term safety of nintedanib in patients with "Systemic Sclerosis associated Interstitial Lung Disease" (SSc-ILD) SENSCIS-ON
|Effective start/end date||12/1/17 → 12/1/22|
- Boehringer-Ingelheim Pharmaceuticals
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.